Xiaolin Wang - 17 Mar 2026 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Reporting relationship: EVP, Clinical Development
Issuer ticker: RVMD
Reported as of: 17 Mar 2026
Net transaction value: -$199,956
SEC form: 4
Accepted by SEC: 19 Mar 2026, 18:53:55 UTC
Prior SEC filing: 03 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Jack Anders, as Attorney-in-fact for Xiaolin Wang

Key filing fact

Xiaolin Wang filed Form 4 for Revolution Medicines, Inc. (RVMD) on 19 Mar 2026.

Key facts

This page summarizes Xiaolin Wang's Form 4 filing for Revolution Medicines, Inc. (RVMD).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 19 Mar 2026, 18:53.

Change

Previous filing in this sequence was filed on 03 Mar 2026.
Current net transaction value: -$199,956.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001849181 Primary reporting owner

Wang Xiaolin

Relationship: EVP, Clinical Development
Address: C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY
Signature: /s/ Jack Anders, as Attorney-in-fact for Xiaolin Wang
Signature date: 19 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RVMD transaction

Common Stock

Sale

Transaction value: $199,956
Shares: -2,010
Change %: -1.7%
Price: $99.48
Shares after: 116,063
Date: 17 Mar 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on November 17, 2025 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after December 15, 2025.

Footnote F2

Includes 48,700 RSUs.

SEC remarks

EVP, Clinical Development